Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : NEOTHERAPEUTICS (NEOT) (NEOTW) -- Ignore unavailable to you. Want to Upgrade?

To: Marty who wrote (598)	11/17/1998 2:36:00 PM
From: Marty	Read Replies (1) \| Respond to of 705

My notes from NEOT conference call Clinical test results more important than anything else. They are in a new phase with lots of activity, lots of tests going on, etc. Most, almost all, of losses are from R & D costs, which are accelerating. They have been drawing down funds from time to time but it has not affected the stock price. They do not announce when they make a draw down and do it when stock is higher in price. There has not been an affect on the market price. They have been quiet lately because they wanted to give their collaborators in the early tests the chance to publish. There were some 35 sites and 4 Universities (UC San Diego, St. Louis U., Mt. Sinai, and another one) participating. Got good results, first that they got response in 90 minutes, the drug was absorbed ok, low dosages, and the half life is such that they can give drug dosage only once a day, NO adverse affects. Seems that the drug acts quickly and does not accumulate in system. Best news is that 17 out of 18 patients on the drug improved which was statistically significant. Reason this is important is that Aricept, for example, took 150 patients 90 days to achieve a clinical difference … to get a statistically significant result that took NEOT only 90 minutes with 18 patients. Tests were independent. NEOT did not design them or input anything or participate. One was 7-day test, another was 90 day and they are in 30-day follow-up period now. Continuing pattern of safety.... NO adverse effects seen. They are getting additional confirmations of new nerve connections and new nerves generated in animals. Animal testing study in Italy found that AIT-082 can reverse effects & prevent further damage to brains. Everything fitting together in studies all over the world... more recognition by medical community More AZ studies scheduled for next year. New spinal cord clinical studies scheduled for early next year. ============== Re strategic alliances: Talking to a number of companies. They don't have to depend on alliance to continue doing research and don't need a pharma deal now. They don't need the money for research a deal would bring because they already have financing. They don't want to risk relying on anyone else's research agenda or priorities. Better to rely on investment banker, market makers, and institutional & retail investors than a pharma alliance. They would need pharma alliance only for marketing, which they don't need now. =================== Neot is the next wave for AZ study. Having more acceptance by peers: Best attended site at the Conference (!) Competitors are getting their drugs, which have different approaches, withdrawn by FDA. The Guilfeld drug is not scheduled to even go into clinical testing until NEXT YEAR. Therefore NEOT will have 2-year head start in clinical testing. ============ Q: Do the institutions get any new info that public doesn't have? A: They seem to respond to newspaper articles more than their own analyst's research. ============= Q: Why clinical trial results took so long to publish? A: Academics just take a long time to publish because of other obligations, even labs take a year to get study reviewed & published. =================== Q: Will they be able to go directly to phase 2 for spinal cord & stroke testing? A: Yes. No more phase 1 testing needed for AIT-082. ========================= Q: Feel that they have adequate patent protection? A: Yes. Their patents cover gene expressions so they have broad protections in US & overseas =========== Q: Will current phase 2 test be done within 90 days? A: Yes ================ They are looking for exact right investment banker now.